Cargando…

Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis

INTRODUCTION: High mobility group box 1 protein (HMGB1) is a nuclear DNA binding protein acting as a pro-inflammatory mediator following extracellular release. HMGB1 has been increasingly recognized as a pathogenic mediator in several inflammatory diseases. Elevated serum levels of HMGB1 have been d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zickert, Agneta, Palmblad, Karin, Sundelin, Birgitta, Chavan, Sangeeta, Tracey, Kevin J, Bruchfeld, Annette, Gunnarsson, Iva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392835/ https://www.ncbi.nlm.nih.gov/pubmed/22348591 http://dx.doi.org/10.1186/ar3747

Ejemplares similares

Antiphospholipid Antibodies in Lupus Nephritis
por: Parodis, Ioannis, et al.
Publicado: (2016)

Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up
por: Gerhardsson, Jakob, et al.
Publicado: (2015)

Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy
por: Parodis, Ioannis, et al.
Publicado: (2015)

Role of early repeated renal biopsies in lupus nephritis
por: Zickert, A, et al.
Publicado: (2014)

Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis
por: Sjöwall, Christopher, et al.
Publicado: (2009)

Interferon (IFN)-λ is a potential mediator in lupus nephritis
por: Zickert, Agneta, et al.
Publicado: (2016)

IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment
por: Zickert, Agneta, et al.
Publicado: (2015)

Urinary aberrations in systemic lupus erythematosus not always indicative of lupus nephritis: a cross-sectional cohort study
por: Karlsson, Linnea, et al.
Publicado: (2023)

Occurrence and localization of FOXP3 + cells in kidney biopsies in lupus nephritis and ANCA-associated vasculitis
por: Zickert, Agneta, et al.
Publicado: (2023)

Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis
por: Parodis, Ioannis, et al.
Publicado: (2019)

Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis
por: Häyry, Aliisa, et al.
Publicado: (2022)

Plasma C4d Correlates With C4d Deposition in Kidneys and With Treatment Response in Lupus Nephritis Patients
por: Martin, Myriam, et al.
Publicado: (2020)

Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis
por: Bolin, Karin, et al.
Publicado: (2013)

Ofatumumab treatment in lupus nephritis patients
por: Haarhaus, Malena Loberg, et al.
Publicado: (2016)

Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus
por: Jönsen, Andreas, et al.
Publicado: (2011)

Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis
por: Wilson, Hannah R., et al.
Publicado: (2019)

IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)
por: Oke, Vilija, et al.
Publicado: (2017)

High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus
por: Oke, Vilija, et al.
Publicado: (2019)

The presence of lupus nephritis additionally increases the risk of preeclampsia among pregnant women with systemic lupus erythematosus
por: Bremme, Katarina, et al.
Publicado: (2021)

Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations
por: Mobarrez, Fariborz, et al.
Publicado: (2016)

TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
por: Idborg, Helena, et al.
Publicado: (2018)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

De novo lupus nephritis during treatment with belimumab
por: Parodis, Ioannis, et al.
Publicado: (2020)

Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus
por: Wirestam, Lina, et al.
Publicado: (2015)

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus
por: Sohrabian, Azita, et al.
Publicado: (2019)

First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis
por: Faustini, Francesca, et al.
Publicado: (2021)

High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts
por: Wähämaa, Heidi, et al.
Publicado: (2011)

Urine Galectin-3 binding protein reflects nephritis activity in systemic lupus erythematosus
por: Faustini, Francesca, et al.
Publicado: (2022)

The Behaviour of Serum Survivin in Patients With Lupus Nephritis
por: Lisboa, Renata Valente, et al.
Publicado: (2022)

ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Genetic Risk Factors in Lupus Nephritis and IgA Nephropathy – No Support of an Overlap
por: Vuong, Mai Tuyet, et al.
Publicado: (2010)

Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis
por: Hardt, Uta, et al.
Publicado: (2018)

Toll-like receptors revisited; a possible role for TLR1 in lupus nephritis
por: Yavuz, Sule, et al.
Publicado: (2021)

Variants in BANK1 are associated with lupus nephritis of European ancestry
por: Bolin, Karin, et al.
Publicado: (2021)

Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case–control study
por: Samuelsson, Isak, et al.
Publicado: (2021)

Urinary and serum levels of high mobility group box 1
por: Nakamura, Toshihiko, et al.
Publicado: (2023)

Mobile health apps for systemic lupus erythematosus and lupus nephritis: a critical appraisal
por: Ramasamy, Akshara, et al.
Publicado: (2022)

Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus
por: Martin, Myriam, et al.
Publicado: (2017)

Hepcidin and arterial stiffness in children with systemic lupus erythematosus and lupus nephritis: A cross-sectional study
por: Atkinson, Meredith A., et al.
Publicado: (2019)

High Mobility Group Box 1 in Human Cancer
por: Rapoport, Bernardo L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ujjnvkr826q2rdkj5s3e6i2e7j